Regeneron
FDA Authorizes REGEN-COV for Post-Exposure Prophylaxis for COVID-19
The FDA revised the EUA for casirivimab and imdevimab, the Regeneron cocktail for post-exposure prophylaxis (PEP) ...
AUGUST 3, 2021
Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients
The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.
FEBRUARY 12, 2019
FDA Approves New Indication for Dupixent for Asthma
Dupilumab inhibits the overactive signaling of IL-4 and IL-13, two key proteins that contribute to the Type 2 ...
OCTOBER 20, 2018
FDA Approves Libtayo as First and Only Treatment for Advanced CSCC
Libtayo is a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 and works by blocking ...
SEPTEMBER 28, 2018
Dupixent Appears to Increase Asthma Control Among Poorly Controlled Patients
When added to standard therapies, Dupixent reduced severe asthma exacerbations and improved lung function in a ...
SEPTEMBER 22, 2017
ACC: Nonstatin Therapies May Be Appropriate for Certain High-Risk Patients
The new recommendations are intended to address current gaps in recommendations for reducing low-density ...
APRIL 4, 2016
